{"id":"https://openalex.org/W7225730992","doi":"https://doi.org/10.25251/5xcv9n94","title":"Concomitant use of glucagon-like peptide-1 receptor agonists in patients with psoriasis or hidradenitis suppurativa receiving bimekizumab: Cross-sectional analysis of US claims data","display_name":"Concomitant use of glucagon-like peptide-1 receptor agonists in patients with psoriasis or hidradenitis suppurativa receiving bimekizumab: Cross-sectional analysis of US claims data","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225730992","doi":"https://doi.org/10.25251/5xcv9n94"},"language":"en","primary_location":{"id":"doi:10.25251/5xcv9n94","doi":"https://doi.org/10.25251/5xcv9n94","is_oa":true,"landing_page_url":"https://doi.org/10.25251/5xcv9n94","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/5xcv9n94","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107463246","display_name":"M Porter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martina Porter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161380689","display_name":"Ana Macedo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ana Macedo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072142037","display_name":"Janek Rudnik","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janek Rudnik","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087135665","display_name":"Aijing Shang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aijing Shang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5151651473","display_name":"Evelina van Ree","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evelina Van Ree","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100423610","display_name":"Chao Song","orcid":"https://orcid.org/0000-0001-6909-7195","observed_orcids":["https://orcid.org/0000-0001-6909-7195","https://orcid.org/0000-0002-7326-1194"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chao Song","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161385811","display_name":"Jeremy Schafer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeremy Schafer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5161381756","display_name":"Pablo De la Cueva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pablo De la Cueva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s862","last_page":"s862"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9365000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9365000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":0.013799999840557575,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.006000000052154064,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.9387999773025513},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8986999988555908},{"id":"https://openalex.org/C2776002364","wikidata":"https://www.wikidata.org/wiki/Q341999","display_name":"Hidradenitis suppurativa","level":3,"score":0.8148000240325928},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.5949000120162964},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5559999942779541},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5006999969482422},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.43869999051094055},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.4106000065803528},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.40610000491142273},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.38830000162124634},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.3431999981403351},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.32910001277923584},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.32199999690055847},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.299699991941452},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2782999873161316},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.2775999903678894},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.27730000019073486},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.26010000705718994}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/5xcv9n94","doi":"https://doi.org/10.25251/5xcv9n94","is_oa":true,"landing_page_url":"https://doi.org/10.25251/5xcv9n94","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/5xcv9n94","doi":"https://doi.org/10.25251/5xcv9n94","is_oa":true,"landing_page_url":"https://doi.org/10.25251/5xcv9n94","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":3,"referenced_works":["https://openalex.org/W1959946112","https://openalex.org/W4402528553","https://openalex.org/W4402776636"],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"Patients":[1,299],"with":[2,91,141,190,226,268,300,312,404,409],"psoriasis":[3],"(PSO)":[4],"and":[5,15,54,66,77,93,123,145,215,237,265,270,286,295,302,329,358,363,422],"hidradenitis":[6],"suppurativa":[7],"(HS)":[8],"have":[9],"higher":[10,292,305],"rates":[11,413],"of":[12,59,75,84,96,105,193,206,279,307,365,438,444],"comorbid":[13,78],"obesity":[14,301],"type":[16],"2":[17],"diabetes":[18],"mellitus":[19],"(T2DM)":[20],"than":[21],"the":[22,57,82,94,114,150,211,410],"general":[23],"population.":[24,424],"Glucagon-like":[25],"peptide-1":[26],"receptor":[27],"agonists":[28],"(GLP-1RAs)":[29],"are":[30,222],"indicated":[31],"for":[32,50,131,135,210,254,361,435],"obesity/T2DM.":[33,79],"Bimekizumab":[34],"(BKZ),":[35],"a":[36,102,142,354,420],"humanized":[37],"IgG1":[38],"monoclonal":[39],"antibody":[40],"selectively":[41],"inhibiting":[42],"IL-17F":[43],"in":[44,63,88,101,149,167,188,293,368,401,414],"addition":[45],"to":[46,243],"IL-17A,":[47],"is":[48],"approved":[49],"moderate-to-severe":[51],"plaque":[52],"PSO":[53,269],"HS.":[55],"Evaluating":[56],"extent":[58],"concomitant":[60,85,194,207,257,280,396,417],"GLP-1RA/BKZ":[61,159,195,208,258],"use":[62,87,160,209,282,290,309,398],"routine":[64,390],"practice,":[65],"characterizing":[67],"patients":[68,90,189,267,311,325,343,403,415,427],"receiving":[69,98,256,326,416],"both":[70,99,327,339],"treatments,":[71],"can":[72],"inform":[73],"management":[74,443],"PSO/HS":[76,92,143,324,340,405,426],"We":[80],"assessed":[81],"prevalence":[83,205,306],"GLP-1RA":[86,281,289,308,328,346,397],"BKZ-treated":[89,370],"characteristics":[95,250],"those":[97,255,296],"treatments":[100],"cross-sectional":[103],"analysis":[104,240,319],"US":[106,127],"claims":[107,120],"data.":[108],"Procedure:":[109],"Data":[110,221],"were":[111,231,350],"taken":[112],"from":[113,121],"Komodo":[115],"Health":[116],"database,":[117],"including":[118],"open/closed":[119],"Medicare":[122],"Commercial":[124],"insurances":[125],"(BKZ":[126],"approval:":[128],"Oct":[129],"2023":[130],"PSO;":[132],"Nov":[133,179,185],"2024":[134],"HS).":[136],"Eligible":[137],"patients:":[138],"\u226518":[139],"years,":[140],"diagnosis,":[144],"\u22651":[146],"BKZ":[147,273,330,376],"claim":[148],"selection":[151,213,262],"period":[152,214],"(Nov":[153],"1,":[154,180,186],"2023\u2013Dec":[155],"7,":[156],"2025).":[157],"Concomitant":[158],"was":[161,172,184,199,204,241,248,283,291],"defined":[162],"as":[163,224],"any":[164],"treatment":[165,437],"overlap":[166,174,177,198],"this":[168],"period;":[169],"index":[170,182,200,252],"date":[171,183,253],"first":[173,197],"day.":[175],"For":[176,338],"before":[178,347],"2023,":[181],"2023;":[187],"multiple":[191],"episodes":[192],"use,":[196],"date.":[201],"Primary":[202],"endpoint":[203,247],"whole":[212],"by":[216,233],"year,":[217],"evaluated":[218],"per":[219],"indication.":[220],"reported":[223],"observed":[225],"95%":[227],"CI.":[228],"Subgroup":[229],"analyses":[230],"performed":[232],"sex,":[234],"age":[235],"group,":[236],"comorbidity;":[238],"sensitivity":[239,318],"restricted":[242],"closed":[244],"claims.":[245],"Secondary":[246],"patient":[249],"at":[251],"treatment.":[259],"Results:":[260],"During":[261],"period,":[263,395],"18,665":[264],"5,082":[266],"HS":[271],"received":[272],"treatment,":[274,418],"respectively.":[275,372],"Prevalence":[276],"(95%":[277],"CI)":[278],"20.1%":[284],"(19.5\u201320.7%)":[285],"23.0%":[287],"(21.9\u201324.2%).":[288],"females":[294],"\u226546\u2013\u226465":[297],"years.":[298],"T2DM":[303],"had":[304,353],"vs":[310,316],"neither":[313],"(PSO/HS:":[314],"48.1%/49.5%":[315],"4.2%/4.3%);":[317],"provided":[320],"similar":[321],"results.":[322],"Among":[323],"(N=3,754/N=1,170),":[331],"mean":[332],"age:":[333],"53.6/46.5":[334],"years;":[335],"females:":[336],"62.2%/74.3%.":[337],"groups,":[341],"most":[342],"(76.7%/82.5%)":[344],"started":[345],"BKZ,":[348],"89.6%/84.6%":[349],"biologic-experienced;":[351],">95%":[352],"cardiometabolic":[355],"condition.":[356],"Semaglutide":[357],"tirzepatide":[359],"accounted":[360],"~40%":[362],"~50%":[364],"prescribed":[366,375],"GLP-1RAs":[367,383],"all":[369],"patients,":[371],"Dermatologists":[373],"often":[374],"(PSO:":[377,384],"39.8%;":[378],"HS:":[379,386],"50.9%)":[380],"but":[381],"rarely":[382],"0.4%;":[385],"1.3%).":[387],"Conclusion:":[388],"In":[389],"clinical":[391],"practice":[392],"during":[393],"study":[394],"(>20%":[399],"overall)":[400],"bimekizumab-treated":[402],"increased.":[406],"This,":[407],"along":[408],"high":[411],"comorbidity":[412],"reflects":[419],"complex":[421],"multimorbid":[423],"Most":[425],"initiated":[428],"bimekizumab":[429],"after":[430],"GLP-1RAs,":[431],"suggesting":[432],"continued":[433],"need":[434],"effective":[436],"these":[439],"inflammatory":[440],"diseases":[441],"alongside":[442],"metabolic":[445],"comorbidities.":[446]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}